ABSTRACT
Background Active esophageal cooling is increasingly utilized as an alternative to luminal esophageal temperature (LET) monitoring for protection against thermal injury during pulmonary vein isolation (PVI) when treating atrial fibrillation (AF). Published data demonstrate the efficacy of active cooling in reducing thermal injury, but impacts on procedural efficiency are not as well characterized. LET monitoring compels pauses in ablation due to heat stacking and temperature overheating alarms that in turn delay progress of the PVI procedure, whereas active esophageal cooling allows avoidance of this phenomenon.
Objective Measure the change in PVI procedure duration after implementation of active esophageal cooling as a protective measure against esophageal injury.
Methods We performed a retrospective review under IRB approval of patients with AF undergoing PVI between January 2018 to February 2020. For each patient, we recorded age, gender, and total procedure time. We then compared procedure times before and after the implementation of active esophageal cooling as a replacement for LET monitoring.
Results A total of 373 patients received PVI over the study period. LET monitoring using a multi-sensor probe was performed in 198 patients, and active esophageal cooling using a dedicated device was performed in 175 patients. Patient characteristics did not significantly differ between groups (mean age of 67 years, and gender 37.4% female). Mean procedure time was 146 minutes in the LET monitored patients, and 110 minutes in the actively cooled patients, representing a reduction of 36 minutes, or 24.7% (p<.001). Median procedure time was 141 minutes in the LET monitored patients and 100 minutes in the actively cooled patients, for a reduction of 41 minutes, or 29.1% (p<.001).
Conclusions Implementation of active esophageal cooling for protection against esophageal injury during PVI was associated with a significantly large reduction in procedure duration.
Competing Interest Statement
CJ reports internship with Attune Medical; MM reports honoraria and consulting from Abbott, Biosense Webster, Attune Medical, Medtronic, Sanofi Aventis, and Philips. JS reports summer internship with Attune Medical.
Funding Statement
CJ reports internship with Attune Medical; MM reports honoraria and consulting from Abbott, Biosense Webster, Attune Medical, Medtronic, Sanofi Aventis, and Philips. JS reports summer internship with Attune Medical.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
First Friday Institutional Review Board (IRB) of NorthShore University HealthSystem. The project was reviewed in accordance with the 2018 Common Rule (45 CFR 46 - as revised).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available upon reasonable request.
